Literature DB >> 2730403

Quantitating the superior visual field loss associated with ptosis.

D R Meyer1, J V Linberg, S R Powell, J V Odom.   

Abstract

The effect of blepharoptosis on the superior visual field was assessed using a series of specially designed contact lenses to simulate ptosis in normal subjects. We found a progressive decrease in the superior visual field at the 90 degree vertical meridian, which was proportional to the degree of simulated ptosis. Our results were in close agreement with both a theoretical model and previous clinical observations. These results are important in evaluating patients contemplating ptosis surgery, as well as in visual field testing for neuro-ophthalmic disorders.

Entities:  

Mesh:

Year:  1989        PMID: 2730403     DOI: 10.1001/archopht.1989.01070010862030

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  5 in total

1.  Prevalence and associated factors of blepharoptosis in Korean adult population: The Korea National Health and Nutrition Examination Survey 2008-2011.

Authors:  M H Kim; J Cho; D Zhao; K I Woo; Y-D Kim; S Kim; S W Yang
Journal:  Eye (Lond)       Date:  2017-03-24       Impact factor: 3.775

2.  Psychosocial implications of blepharoptosis and dermatochalasis.

Authors:  J D Bullock; R E Warwar; D G Bienenfeld; S L Marciniszyn; R J Markert
Journal:  Trans Am Ophthalmol Soc       Date:  2001

3.  Modified visual field test for ptosis surgery (Leicester Peripheral Field Test).

Authors:  S F Ho; A Morawski; R Sampath; J Burns
Journal:  Eye (Lond)       Date:  2011-01-21       Impact factor: 3.775

4.  Tangent screen perimetry in the evaluation of visual field defects associated with ptosis and dermatochalasis.

Authors:  Molly L Fuller; César A Briceño; Christine C Nelson; Elizabeth A Bradley
Journal:  PLoS One       Date:  2017-03-29       Impact factor: 3.240

5.  Impact of Single Eyelid on Superior Visual Field.

Authors:  Takeshi Kitazawa; Shunsuke Yuzuriha
Journal:  Ann Plast Surg       Date:  2022-04-01       Impact factor: 1.539

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.